Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Blood-Brain Barrier Opening Device Enables Liquid Biopsy Tests in Brain Tumor Patients

By HospiMedica International staff writers
Posted on 27 Oct 2023

The blood-brain barrier (BBB) serves as a protective shield for the brain, strictly controlling the substances that can move from the bloodstream into the brain. More...

This barrier not only keeps harmful molecules at bay but also limits the reach of potentially beneficial drugs and diagnostic markers, thus preventing measurement using a blood test. Now, a non-invasive medical device that reversibly opens the BBB exactly where it is needed can pave the way for precision medicine, delivering drugs, and measuring circulating biomarkers via a blood test to diagnose and track brain diseases.

Cordance Medical (Mountain View, CA, USA) has developed the NeuroAccess device aimed at adults aged 22 and older who have known or suspected brain tumors. The device allows healthcare experts to non-invasively raise the levels of cell-free DNA (cfDNA) in the bloodstream, enhancing the performance of liquid biopsies for oncology. The device employs focused ultrasound coupled with microbubbles to safely and temporarily open the BBB. With its portable design, the goal is for the NeuroAccess device to be used for SonoBiopsy procedures in various healthcare settings, from community clinics to hospitals.

Earlier in the year, initial studies confirmed the safety and feasibility of using the SonoBiopsy technique in patients with brain tumors. Previous research using focused ultrasound and microbubbles to open the BBB has shown promise for treating various neurological conditions, such as glioblastoma, brain metastasis, Alzheimer's, and Parkinson's. Now, the U.S. Food and Drug Administration has given the NeuroAccess device a Breakthrough Device Designation, indicating its transformative potential for meeting the medical needs of brain tumor patients by offering a safer way to obtain molecular characterization of their tumors.

"This Breakthrough Device Designation from the FDA is a pivotal milestone for Cordance Medical and for patients requiring more efficacious diagnostic solutions," said Ryan Dittamore, CEO of Cordance Medical. "We are keen to continue our clinical trials and to collaborate closely with the FDA to bring this groundbreaking technology to market."

Related Links:
Cordance Medical 


Gold Member
Handheld Blood Glucose Analyzer
STAT-Site
Radiology Monitor
MDNC-6121 Barco Nio Color 5.8MP
Medical Examination & Procedure Light
Vega 80
POC Respiratory/Sore Throat Test
BIOFIRE SPOTFIRE (R/ST) Panel
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Surgical Techniques

view channel
Image: The study is the first to demonstrate a single nanomaterial platform that combines rapid blood clotting, activation of the body’s own latent growth factors, recruitment of bone-forming stem cells and enhanced bone regeneration. (Image Credit: Stef Zingsheim/University of Sydney)

Nanobone Material Activates Natural Repair Signals to Regrow Bone

Cleft lip and palate is a birth defect that affects about 1 in 700 children and occurs when parts of the upper lip or roof of the mouth do not fully fuse during pregnancy. Repairing the resulting jawbone... Read more

Medical Imaging

view channel
Images from patient T1, who had menstrual cycle–dependent right shoulder pain. (A) Maximum-intensity-projection images show abnormal findings for right diaphragm (arrowhead), bilateral round ligaments, peritoneum around bilateral ovaries, and left fallopian tube. Combined PET/MRI show hyperintense lesion with focal uptake inferior of right diaphragm, indicative of endometriosis (arrowhead, B). Confirmatory laparoscopy demonstrated extensive pelvic disease and implants of right diaphragm (C) that stained intensely positive for FAP (D).  (Image Credit: Schindler P, Brandt J, Bobe S, et al. Initial results of FAPI PET/MRI to assess the extent of endometriosis. J Nucl Med. 2026;67(8):1232–1238. doi:10.2967/jnumed.125.271376)

Targeted PET/MRI Improves Detection and Preoperative Mapping of Endometriosis

Endometriosis is a chronic inflammatory condition in which endometrial-like tissue grows outside the uterus, causing pelvic pain, infertility, and reduced quality of life. Conventional imaging can underestimate... Read more

Business

view channel
Image: Sempresto’s Smartphone-Integrated Epinephrine Auto-Injector Wins Red Dot Design Award (Photo courtesy of Sempresto)

Smartphone-Integrated Epinephrine Auto-Injector Concept Wins Red Dot Design Award

Severe allergic reactions can escalate rapidly and require prompt epinephrine, yet many at-risk patients do not consistently carry their auto-injector. With food allergies affecting an estimated 220 million... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.